Adalimumab reduced the signs and symptoms of AS and induced partial remission for up to 2 years. The long-term safety profile was similar to the short-term safety profile. Trial registration information: NCT00085644.
No takes yet. Share an insight, caveat, or question.
Heijde et al. (2008) studied this question.